SGLT2 inhibitors vs. GLP-1 agonists: Comparative progression of renal disease

被引：0
|
作者：
Stevens, Lauren [1 ]
Bowe, Andy [1 ]
Schwab, Phil [1 ]
Tindal, Michael [2 ]
Bloomfield, Andrea [2 ]
机构：
[1] Humana Healthcare Res, Louisville, KY USA
[2] Humana Pharm Solut, Louisville, KY USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [1] Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
    Poonawalla, Insiya
    Bowe, Andy
    Tindal, Michael
    Meah, Yunus A.
    Schwab, Phil
    [J]. DIABETES, 2020, 69
  • [2] SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Rolek, Bartosz
    Haber, Mateusz
    Gajewska, Magdalena
    Rogula, Sylwester
    Pietrasik, Arkadiusz
    Gasecka, Aleksandra
    [J]. JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (08)
  • [3] SGLT2 INHIBITORS VS. GLP1 AGONISTS AS TREATMENTS FOR OSTEOARTHRITIS
    Jafarzadeh, S. Reza
    Ma, Kevin
    Peloquin, Christine E.
    Felson, David
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S41 - S42
  • [4] Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease
    Patorno, Elisabetta
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Kim, Dae H.
    Everett, Brendan M.
    Bessette, Lily G.
    Kim, Seoyoung C.
    [J]. DIABETES, 2019, 68
  • [5] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [6] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [7] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [8] Association of SGLT2 Inhibitors and DPP-4 Inhibitors vs. GLP-1 Agonists with Incident CKD in US Veterans
    Kalantar-Zadeh, Kamyar
    Rhee, Connie
    Narasaki, Yoko
    You, Amy S.
    Dashputre, Ankur A.
    Sumida, Keiichi
    Thomas, Fridtjof
    Streja, Elani
    Potukuchi, Praveen Kumar
    Kovesdy, Csaba P.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 697 - 698
  • [9] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    [J]. LANCET, 2021, 398 (10296): : 262 - 276
  • [10] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
12345